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Summary: This review summarizes pathobiochemical aspects of diseases, in which cytoskeletal components
play a crucial role in pathogenesis. An attempt to classify the disorders on the basis of phenotypic changes
that occur in microfilaments, intermediate filaments and microtubuli was unsuccessful. Three groups of
disorders are presented:
1. cytoplasmic inclusions in specific diseases (merely descriptive);
2. diseases with genetic defects in cytoskeletal proteins (a chain of causality from defect to phenotype, in
some cases with large gaps);
3. diseases with suspected involvement of cytoskeleton (hypothetical causal chain).
Microfilaments are involved in certain pathogenetic processes on account of defects in their associated
proteins; in Duchenne muscular dystrophy, dystrophin is defective, while the defective protein in Rett syndrome
is synapsin. Defects in spectrin and membrane anchor proteins lead to disorders of the red cell membrane
skeleton (congenital haemolytic anaemias). Intermediate filaments accumulate in some types of cytoplasmic
inclusions, together with ubiquitin (Mallory bodies, desmin accumulation in some myopathies and others). A
pathogenetic interpretation of this phenomenon is lacking. A genetic defect in certain types of keratin is the
cause of epidermolysis bullosa. Interesting preliminary results are reviewed that reveal the crucial role of
cytoskeletal components in a further group of diseases (intrahepatic cholestasis, Alzheimer disease, pemphigus).
These disorders are currently under investigation, or are of theoretical interest with respect to the cytoskeleton.
Specific reactions of cytoskeletal components in serum, which might be used diagnostically, have not been
found.
Introduction biochemical aspects. Cytoskeleton research has re-
^"^ ' "* ^ "*"The cellular cytoskeleton, consisting of actin fila- ,ments, microtubules and intermediate filaments, is ^ochemical insights. The most recent example of
involved in many fundamental processes of the cell th!f .1S the role °f Cadhenns and ^smosomes in cell-
(see reviews 1-8). An ever increasing number of ^ >nteractlon' and their involvement in the distur-
publications deals with variations of the cytoskeleton bar;ces Aat occur m P^P^gus, which are currently
in disease. Literature on the morphological aspects of Under "»vertigation. On the other hand, new findings
these disorders has been the subject of reviews, in » fytoekdelon related diseases have implications for
which the affected proteins are listed in long tables f1 rblology' the current examPle bein* the search for
(9, 10 and others). Knowledge about the cytoskeleton the functlon of dystr°Phin in striated muscle·
and its disorders, collected by different disciplines This generalized presentation represents an attempt
from histology to biochemistry, would now seem to to obtain a deeper insight by comparing and bringing
justify the present attempt to summarize the patho- together information in the cytoskeleton in different
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organs. Genetic deficiencies or anomalies of G-actin
and tubulin, the main components of the cytoskele-
ton, have not been described in the literature, perhaps
because they are lethal. Defects of actin- and tubulin-
associated proteins, of spectrin, and of intermediate
filaments are discussed in the present review. Refer-
ence is also made to the storage of intermediate fila-
ments and ubiquitin in cytoplasmic inclusions and
their relation to diseases. The review closes with a
glance at clinical chemistry and the question of
whether cytoskeletal components can be found in
serum and if their determination may be of diagnostic
importance.
Proteins of the Cytoskeleton
The term cytoskeleton includes 3 different structures
which, like cellular organelles, subdivide cellular
space: microtubuli (11 — 18), intermediate filaments
(5) and microfilaments (3, 6-8, 14, 15, 20) (tab.l).
These 3 organelles form a dense network, making
contact with each other and other organelles (21, 22),
especially the plasma membrane (3, 6, 7, 14, 15, 20)
(actin filaments), while its extracellular components
mediate cell-cell interaction (1—3, 14, 15, 23). Two
properties of the cytoskeleton are responsible for its
important role in cell biology. Firstly, in contrast to
the permanency normally associated with a skeleton,
the cytoskeletal filaments are not stable or static parts
of the cell. Receptor mediated stimuli (3, 14, 20) and
other intracellular conditions (Ca, pH) lead to poly-
merisation or depolymerisation, to enlargement or
reduction of the cytoskeletal network within seconds.
The relation between monomers and polymers (nor-
mally 1:1) can be shifted very quickly. Secondly, actin
filaments and microtubuli associate specific proteins
(actin associated proteins: (6, 7, 9, 24); microtubuli
associated proteins: (4, 11-13). A large number of
these proteins modify the structure and properties of
the filaments and link them with other structures and
with the plasma membrane (tab. 1). The functional
significance of the association of cytoplasmic enzymes
with microfilaments is not yet clear (25, 26).
Microtubuli are normally long hollow tubes of pro-
teins with an outer diameter of 25 nm (tab. 1) (4, 11,
13, 14). They are formed from molecules of tubulin,
each of which is a heterodimer consisting of two
tightly linked globular subunits (a- and -tubulin, Mr
50000). Each heterodimer binds 2 molecules of GTP.
The polymer, i. e. the micro tubule, is a polar structure -
with a plus (fast growing) and a minus (slow-growing)
end. Special structures in the cell bind and stabilize
microtubule ends. Most microtubules grow from the
centrosome, which acts as a microtubule-organizing
centre. γ-Tubulin, a newly identified member of the
tubulin family, whose concentration in individual cells
is extremely low (16, 17), is a universal component of
microtubule organizing centres (mainly centrosomes)
and it controls microtubule nucleation in vivo (18).
The most prominent example of microtubule assem-
bly is the mitotic spindle, which is affected by various
drugs (colchicine, taxol, vinblastine). Λ large and ever-
increasing number of proteins, known as microtubuli
associated proteins, interact and often coloc lize with
cellular microtubules. In the absence of well-defined
functions for most of the microtubuli associated pro-
teins known to date, they are usually classified ac-
cording to their size (12). A special class of microtu-
buli associated proteins (kinesin, dynein) uses the
energy of ATP hydrolysis to move unidirectionally
along a microtubule, providing a mechanism for the
spatial organisation and directed movements of or-
ganelles in the cytoplasm (27).
Intermediate filaments are 8 — 10 nm in diameter,
which is "intermediate" between actin filaments and
microtubules. They are formed from 4 types of fibrous
polypeptides with a wide range of sizes (MT 40000 —
130000) (tab. 1). All types share a similar central
region which forms an extended α-helix with three
short interruptions (5, 19). The filaments are formed
from a dimeric subunit by association with one an-
other in large overlapping arrays. Intermediate fila-
ments are extremely stable and there is not a large
pool of unpolymerized intermediate filament proteins
in the cell, as there is for actin and tubulin. The
globular domains at either end allow the intermediate
filament to vary in order to match the requirements
of the particular cell type. The occurrence of different
globular domains according to the cell type is so
specific that they provide a distinctive "fingerprint",
which is useful for tracing the origin of tumours.
Intermediate filaments are thought to protect cells
against mechanical stress and to provide mechanical
support to the cell and its nucleus. However, they
differ in two functional aspects from actin filaments
and microtubules. Firstly, they are relatively stable
and more "skeletonlike". Secondly, their properties
are determined by the amino-terminal and carboxyl-
terminal domains of the intermediate filament, rather
than by associated proteins.
The Μτ 42 000 globular actin monomer (G-actin) has
been highly conserved during evolution (7, 8). It has
a bound nucleotide (ATP) which is hydrolysed to
ADP on polymerization. Actin can be polymerized
into double-helical actin filaments (F-actin), which
usually contain up to a thousand G-actin molecules
per filament. Polymerization is a very complicated
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Tab. 1. Components of the cytoskeleton.
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fast process with a balanced equilibrium between G-
actin and actin filaments, depending on intracellular
conditions such as the presence of actin binding pro-
teins (6, 28); it is also influenced by certain drugs
(cytochalasin, phalloidin) (29). In striated muscle, F-
actin (thin filaments) is involved in sarcomere struc-
ture, together with myosin (thick filaments), the reg-
ulatory proteins, tropomyosin and troponins I, T and
C. The myosin/actin ratio is 1 : 6. In non-muscle cells
this ratio is 1 :100. Here also, the myosin filaments
are oriented parallel to actin filaments, thus providing
the biological substratum for a range of subcellular
motility events (30). Movement occurs not only by
the sliding filament mechanism as in muscle cells, but
also by rapid assembly or disassembly of actin fila-
ments, interactions between actin filaments them-
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selves, and between filaments and other proteins (2,
28). Thus specific interactions of either G- or F-actin
with actin-associated protein determine the different
molecular organisation and cellular locations of actin.
In this way cellular functions dependent on subcellular
motility are effected by microfilaments: endocytosis,
exocytosis, secretion, movement of vesicles, internal-
ization of receptor-bound material, and many Golgi-
related activities (6, 28). Moreover, actin filaments
play a role in the control of cell shape, in the regu-
lation of the dynamics of the cytoplasmic matrix, and
in intracellular cytoplasmic convection. Stress fibres
are prominent features of the cytoskeleton of cultured
cells, consisting mainly of actin with the minor com-
ponents myosin, -actinin and tropomyosin (24). G-
actin can be divided into 4 subdomains each respon-
sible for binding specific actin associated proteins
(DN-ase binding loop, hydrophobic loop and others)
(8). Moreover, different cytoplasmic proteins (tab. 1)
and enzymes, e.g. glycolytic enzymes (25, 26) and
polysomes (22) are associated with actin filaments. A
specific feature of actin filaments is their close con-
nection with the plasma membrane, forming an es-
pecially dense network just beneath it which consti-
tutes the cell cortex (7, 20). These concentrations can
be mediated by direct coupling to phospholipids (31)
or via linker proteins. Calpactins are such a group of
proteins, displaying Ca-dependent binding to phos-
pholipids and actin (32). Actin is one of the most
abundant and therefore best studied eukaryotic pro-
teins. Current knowledge of actin is reviewed in 1. c.
(6-8,14,15,20).
Cytoplasmic Inclusions
Several chronic human degenerative diseases (33 — 50)
show intracellular extralysosomal inclusions, contain-
ing intermediate filaments which can be demonstrated
with immunohistochemical methods:
— desmin in cytoplasmic inclusions in special my-
opathies(35, 38-41),
— cytokeratins in Mallory bodies in alcoholic liver
disease (36, 42-46),
— neurofilaments in the Lewy bodies in Parkinson
disease (47, 48), neurofibrillary tangles in Alz-
heimer disease (37, 49), and Pick's body in Pick's
lobar atrophy (34),
— glial fibrillary acidic protein and vimentin in Ro-
senthal fibres in astrocytoma.
Most, if not all of the cytoplasmic inclusions that
contain intermediate filaments also contain ubiquitin,
a regulatory, highly conserved protein of 76 amino
acids, which plays a role in the degradation of ab-
normal proteins (51, 52). Proteolysis by the ubiquitiri
system complements the lysosomal system and in-
volves two discrete steps. Initially, in an ATP-depend-
ent reaction, ubiquitin is covalently linked to the
protein substrate. A single, destabilizing amino acid
at the amino terminus facilitates the attachment of
multiple copies of ubiquitin to specific lysine residues
in the target protein. The protein moiety of the con-
jugate is subsequently degraded by an ATP-dependent
protease with the release of free and reutihzable ubi-
quitin. Denatured or misfolded proteins and those
containing otherwise abnormal amino acids are pre-
fered substrates of ubiquitination (44, 53).
The pathobiochemical mechanisms of conjugation of
intermediate filaments with ubiquitin is not under-
stood. Lowe and coworkers (33, 34) suggested that
two related but opposing processes occur in chronic
degenerative diseases: the deleterious effects of the
pathogenetic insult which can be chemical or viral,
and a cellular cytoprotective response to the insult.
Therefore, intermediate-filament-containing, ubiqui-
tinated inclusions may be hallmarks of cellular at-
tempts to eliminate pathogenetic insults by activating
protein degradation mechanisms. According to this
view, the formation of such inclusion possibly repre-
sents a secondary reaction to cell injury of many types,
especially of neuronal aging. However, it is not clear
whether the inclusion bodies are signs of increased,
failed or defective proteolysis. Cytoplasmic inclusions
are therefore very important as morphological-dia-
gnostic signs but of little help in constructing a chain
of pathogenetic events.
Desmin and Cytoplasmic Inclusions in Myopathies
Desmin is the intermediate filament of the muscle cell.
Desmin filaments connect the edges of the Z-disc in
striated muscle cells.
About forty different congenital myopathies are de-
fined by clinical and morphological criteria. Three of
them (central core disease, centronuclear myopathy,
and nemaline/rod myopathy) regularly present with
cytoplasmic inclusions containing accumulated des-
min (38). Other myopathies or cardiomyopathies oc-
casionally show inclusions of the desmin-type (35,
38).
Central core disease originally described by Shy &
Magee (39) obtained its name from the observation
of discrete zones (cores) devoid of oxidative enzymes.
This disorder selectively affects type I fibres and pre-
disposes the carrier to malignant hyperthermia (38,
40).
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Nemaline or rod myopathy is an autosomal dominant
trait showing clusters of small rod bodies, usually
found in type I fibres near the Z-band and often in
combination with it ((38), see 1. c. (40) for older lit-
erature).
Myotubular myopathy (41) is an autosomal recessive
or X-linked recessive disease. The histologic abnor-
mality led the authors to postulate an arrest of muscle
fibre maturation at the myotubular (10 — 12 week)
stage of embryogenesis (38, 40).
Clinically, all 3 myopathies show muscle hypotonia,
and a non-progressive course is common. A neuro-
genic pathomechanism is likely, although the heredi-
tary defect in all three myopathies is unknown (38,
40). Hence, the existence of inclusion bodies cannot
be related to a common pathobiochemical cause. Con-
versely, knowledge of the composition of these inclu-
sions has not helped the search for the pathobiochem-
ical mechanism of the 3 myopathies.
Keratin in Cytoplasmic Inclusions (Mallory Bodies)
In 1911 Mallory described a peculiar hyaline degen-
eration of the cytoplasm of liver cells in patients dying
with alcoholic cirrhosis (42). Identical hyaline material
has been described in a diverse array of non-alcoholic
liver diseases such as primary biliary cirrhosis, Wil-
son's disease, Indian childhood cirrhosis, chronic cho-
lestasis, and even in extrahepatic locations such as the
lung after exposed to asbestos, radiation and other
forms of injury (54, 55). Mallory bodies can be pro-
duced in mouse hepatocytes by chronic griseofulvin
intoxication (56). Because griseofulvin (like colchi-
cine) causes microtubular depolymerization, a rela-
tionship between microtubules and Mallory bodies
has to be assumed (see 1. c. (56) for review). Mallory
body filaments consist of cytokeratin. Keratins are
divided into 2 subclasses: 11 acidic (type I) keratins
and 8 neutral to basic (type II) keratins. Intermediate
filaments are formed from equiinolar amounts of type
I and type II keratin (5, 19). Mallory bodies contain
cytokeratins with very high molecular masses, so that
a posttranslational modification may be involved in
Mallory body pathogenesis (36). Mallory bodies also
contain ubiquitin (44) and different polypeptides (36,
45, 46). They have been subdivided into 3 morpho-
logical types representing different stages in their ev-
olution (43). The formation of Mallory bodies is ac-
companied by derangement and even loss of the ker-
atin cytoskeleton of hepatocytes. This is perhaps the
result of the accumulation of keratin in Mallory bod-
ies (45, 46). They can also be observed in cholestasis
(57).
Neurofilaments in Cytoplasmic Inclusions
Neurofilament proteins are characteristic for neuronal
cells. They accumulate in the Lewy bodies in Parkin-
son disease (47, 48), as Pick bodies in Pick's lobar
atrophy and as neurofibrillar tangles in Alzheimer
disease (37, 49, 50, 58, 59). Their appearance is not
specific for the 3 diseases and seems to reflect a
neurodegenerative disorder. Obligate components of
the 3 inclusions are neurofilaments and ubiquitin, but
many other components are involved and the litera-
ture is full of observations obtained by immunohis-
tochemical methods.
Glial Fibrillary Acidic Protein
in Cytoplasmic Inclusions
Glial fibrillary acidic protein is the intermediate fila-
ment of glial cells (astrocytes and some Schwann cells).
Cytoplasmic inclusions are described as Rosenthal fi-
bres in astrocytoma (together with vimentin as a
minor component) (60).
Vimentin is the intermediate filament of mesenchymal
cells (see review (61)). A pathobiochemical relation-
ship between vimentin and specific diseases has not
been established. Another intermediate filament is
nuclear lamin, but it has not been implicated in spe-
cific diseases.
Disorders of Red Cell Membrane Skeleton:
Hereditary Spherocytosis and Elliptocytosis
The cytoskeleton of the erythrocyte has a specialized
composition (3, 7, 14, 62, 63). The main component
is spectrin, a stable dimer of two chemically distinct
peptides ( -chain, Mr 240000, ß-chain, MT 220000),
which are oriented in parallel and intertwined. The
dimer contains rather rigid helical domains separated
by flexible regions composed of highly hydrophobic
domains. The dimers associate end to end forming a
tetrameric protein of 200 nm length. The tails of the.
tetramers bind to actin oligomers which are 12—14
monomers long. The actin oligomers form the nodes
of the network. Every node binds an average of 5
spectrin tetramers, and the association is strengthened
by band 4.1 proteins (fig. 1) (64, 65).
The cytoskeletal network is attached to the membrane
by at least two proteins: ankyrin and protein 4.1.
Ankyrin binds simultaneously to the ß-spectrin sub-
unit and to the Cytoplasmic N-terminal domain of the
anion transporter (= band 3 protein). Protein 4.1
interacts with glycophorin C, the major sialoglyco-
protein. Many other proteins are involved in this
Eur. J. Clin. Chem. Clin. Biochera. / Vol. 31,1993 / No. 8
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a) Cross section












Fig. 1. Schematic model of human red blood cell cytoskeleton
according to By er s & Branton^ Liu et ah
a) Cross section: modes of interaction of cytoskeleton-
associated proteins with intrinsic membrane pro-
teins. The cytoskeleton is anchored by ankyrin and
band 3 protein and at the cross points by the com-
plex actin, protein 4.1 and glycophorin to the eryth-
rocyte membrane.
b) Spectrin meshwork with hexagonal lattice linked by
junctional complexes to the membrane.
network. A schematic presentation is shown in figure
1. The red blood cell cytoskeleton has been the subject
of many authoritative reviews (3, 7, 14, 62, 63).
The erythrocyte cytoskeleton is a major determinant
of membrane shape and flexibility and helps to control
lipid organisation and mobility, and the topography
of integral proteins. Plastic deformation of red blood
cells is probably due to realignment of dynamic skel-
etal interactions in response to the stress of distortion.
Defects in the network permit membrane budding
and fragmentation (66) and, in the most extreme
cases, result in a spherical shape of the erythrocyte
comparable to that of isolated phospholipid vesicles.
Today it is clear that three red cell disorders charac-
terized by shape changes are caused by defects of
membrane cytoskeletal components. These 3 anae-
mias are: hereditary spherocytosis, hereditary ellip-
tocytosis, and hereditary pyropoikilocytosis.
The characteristic erythrocyte shape in hereditary
spherocytosis is the spherocyte: a cell with decreased
surface area per unit volume (mean corpuscular vol-
ume is usually normal, mean corpuscular haemoglo-
bin concentration is increased to between 350 and 380
g/1). Many metabolic abnormalities have been iden-
tified in hereditary spherocytosis red cells, but except
for the cytoskeleton variations, the majority are be-
lieved to be secondary. Erythrocyte membranes from
almost all hereditary spherocytosis patients are spec-
trin-deficient. The mechanism is under debate (67).
The condition presents a clinically broad picture, ex-
tending from neonatal hereditary spherocytosis in the
form of jaundice with poor prognosis in the first few
days of life, to cases of compensated haemolysis, in
which red cell production and destruction are bal-
anced. In view of this heterogeneous presentation, the
genetic defect of spectrin may exist at different genetic
loci. Furthermore, spectrin deficiency is often com-
bined with defects of intrinsic membrane proteins (67,
68).
In hereditary elliptocytosis the defect lies in the skel-
etal proteins, usually as a combination of a spectrin
abnormality and a deficiency of an intrinsic mem-
brane protein. Partial transition to spherocytosis with
splenic conditioning is observed only in very severe
cases (for review see 1. c. (69)).
The thermic abnormality of spectrin leads to heredi-
tary pyropoikilocytosis. Hereditary pyropoikilocyto-
sis is thought to be related to hereditary elliptocytosis,
since both have been reported in the same family (69).
Hereditary pyropoikilocytosis is a rare disorder char-
acterized by bizarre-shaped microcytic cells (for re-
view see 1. c. (69)).
Although this is an oversimplification, the 3 heredi-
tary haemolytic anaemias are presented together in
table 2. In nearly all cases a defect/deficiency of spec-
trin is basic to the condition, combined with a defi-
ciency of an anchor membrane protein. The clinical
and genetic picture is particularly broad in the sub-
types of hereditary elliptocytosis. In all cases hae-
molysis is markedly ameliorated by splenectomy.
However, the specific pathobiochemical mechanism(s)
responsible for splenic sequestration and red cell de-
struction remains to be defined.
Epidermolysis Builosa
Epidermolysis bullosa involves a clinically and path-
ogenetically heterogeneous group of disorders char-
acterized by trauma-induced blistering of the skin.
Usually epidermolysis bullosa is classified as epider-
molysis bullosa simplex, junctional epidermolysis bul-
losa, or dystrophic epidermolysis bullosa according
to the blister site observed in electron microscopy
(70). In epidermolysis bullosa simplex the split in
blister formation is within the basal cells of the epi-
dermis, such that the base of the blisters contains
remnants of the basal plasma membrane and the top
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 8
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Congenital haemolytic anaemia (dominant
or recessive) with:
1. Deficiency of spectrin. Speculations:
— biosynthesis diminished
— biosynthesis of an unstable spectrin
— binding of spectrin at the membrane
insufficient
2. Defects of membrane proteins (protein
4.1., glycophorin C)
3. Thermal sensitivity of spectrin (normal
spectrin denatures in 10 min at 49 °C, red
cells fragment at this temperature)
4. Splenic conditioning
5. Destruction in the spleen
(Correlates with the se-
verity of the disease)
Progressive loss of mem-
brane surface and decrease







fect with diminished self
association)
Purified spectrin denatures in 10 min at 45 °C
contains the nucleus and supranuclear portion of the
basal cell. In junctional epidermolysis bullosa the split
is within the basement membrane zone in the lamina
lucida. In the very severe dystrophic epidermolysis
bullosa (in most cases the fourth decade of life is not
survived) the split is in the upper dermis.
The apparently uniform clinical picture of epider-
molysis bullosa should be further differentiated by
taking into account pathobiochemical results. In dys-
trophic epidermolysis bullosa the structures known as
anchoring fibrils are affected; since the major con-
stituent of anchoring fibrils is collagen VII, dystrophic
epidermolysis bullosa is probably a collagenosis (70,
71, 72).
Epidermolysis bullosa simplex and junctional epider-
molysis bullosa are different phenotypes of an auto-
somal dominant heredited keratin defect (71, 72),
although epidermolysis bullosa simplex is also mani-
fested in several subtypes, named after the first au-
thors to describe them (Weber-Cockayne, Köbner,
Dowling-Meara).
The genes encoding the type I keratins are on chro-
mosome 17q, those encoding type II on chromosome
12q (70). Of the many possible heterodimers, at least
20 are found in different layers of skin epithelium,
and another 8 in hair and nail. The localisation of
the mutation determines the clinical presentation.
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a fatal progressive
myopathy affecting approximately 1 in 3000 boys. It
is an X-linked recessive disorder and is allelic to
Becker muscular dystrophy, a less severe and less
frequent condition. In 1988 a protein called dystro-
phin was identified as the defective protein in Duch-
enne muscular dystrophy by the research groups of
Koenig, Monaco, Kunkel and Hoffman (73 — 78). Dys-
trophin is a very large protein (MT 427000) present
in healthy muscle (0.002% of total proteins in muscle).
Extremely small quantities are also found in heart
and brain. Amino acid sequence homologies with
actinin and spectrin and structural analysis led to the
conclusion that dystrophin is a cytoskeletal protein
(74—77). It consists of 4 domains. The N-terminal
domain with 240 amino acids is highly homologous
to cytoskeletal ot-actinin. The N-terminal domain is
linked to a large rod-like domain with 24 repeats of
109 amino acids, which resembles the repeat domains
of spectrin and -actinin. Spacer sequences which do
not align with the repeat consensus are present at the
Eur. J. Clin. Chem. Clan. Biochem. / Vol. 31,1993 / No. 8
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beginning and the end of the domain. The high proline
content of the spacers suggests that they represent
hinges (78). The next domain is cysteine-rich and is
related to the C-terminus of α-actinin. The C-terminal
domain contains 420 amino acids and does not match
with any other previously characterized proteins. Us-
ing different antibodies, dystrophin was shown to be
localized at the cytosolic face of the sarcolemma in
normal myotubes (79).
Duchenne muscular dystrophy muscle tissue showed
no immunoprecipitation with antibodies against dys-
trophin, while muscle tissue from the mild Becker-
Kiener dystrophy showed an incomplete precipitation
zone with gaps (80).
The central problem of topical Duchenne muscular
dystrophy research has been to relate the defect of
this metabolically inert cytoskeletal protein to the
various metabolic disorders which accompany the dis-
ease. In the current model of pathogenesis, dystrophin
protects the surface membrane of the myotubule from
pleating charges (78, 79). The absence of dystrophin
in Duchenne muscular dystrophy leads to lesions of
the surface membrane resulting in Ca-influx with sub-
sequent activation of Ca-dependent phospholipases
and proteinases.
Further evidence for the relationship between dystro-
phin and metabolism is provided by the results of
Ervasti et al. (81). They showed that the localization
of dystrophin at the cytoplasmic face of the sarco-
lemma results from a tight association of dystrophin
with an integral membrane protein consisting of 4
glycoproteins (82). The concentration of one of these
is greatly reduced in Duchenne muscular dystrophy
muscle. Thus, the absence of dystrophin may lead to
the loss of a dystrophin-associated glycoprotein. This
phenomenon is paralleled in elliptocytotic erythro-
cytes, where the absence of cytoskeletal proteins is
accompanied by a loss of surface membrane compo-
nents (splenic conditioning) (66). It was speculated
that the lost glycoprotein in dystrophic muscle might
play a role in the regulation of intracellular Ca (81).
Besides the ambiguities in the relation between dys-
trophin and Duchenne muscular dystrophy metabo-
lism, there are other uncertainties. Dystrophin is also
, absent in animal forms of dystrophy such as xmd
dogs, mdx mice and a genetic form in cats. In all
these models the disease takes a very benign course.
Mdx mice do not have a shortened life expectation
(reviewed in 1. c. (83)). Furthermore, dystrophin is also
found in brain (84) and heart (85,86), but in Duchenne
muscular dystrophy these two organs show not oblig-
atory symptoms.
Ren Syndrome
The /te/r-syndrome is an X-linked neurodegenerative
disorder whose heredity is not clear (87, 88). Because
Ren syndrome is found in females only, a new X-
chromosomal mutation with embryonic lethality for
males is thought to exist. Recently, about 1000 cases
have been published. The disease takes a progressive
course with extrapyramidal disorders and atrophy of
the brain.
Circumstantial evidence suggests that a defect in syn-
apsin I gene structure or expression might be involved
in Rett syndrome (87. 88). This evidence includes
analysis of structural and functional aspects of syn-
apsin I primary structure, and characterization of
synapsin I messenger RNAs.
Synapsin I is a neuron-specific phosphoprotein. In a
phosphorylation-dependent process, it binds to small
synaptic vesicles and actin-filaments, and becomes
localized on the cytoplasmic surface of the vesicles. It
has been hypothesized that dephosphorylated synap-
sin I inhibits neurotransmitter release by anchoring
the synaptic vesicles to the actin filaments of the nerve
terminal (89). There seem to be 2 pools of transmitter
in the presynaptic nerve terminal, one associated with
actin filaments, the other representing a "free" pool
which is available for release. The size of these pools
is thought to be regulated by the reversible phospho-
rylation of synapsin I through various signal tratis-
duction pathways.
Alzheimer Disease
Alzheimer disease is the most common form of adult-
onset dementia and approximately 10% of the pop-
ulation over the age of 65 are affected (e. g. (91, 92)).
The major problem for research on the aetiology of
this condition is its clinical heterogeneity; it may pres-
ent as a familial early-onset, familial late-onset, or
sporadic form. The literature on the pathobiochemical
aspects of Alzheimer disease is enormous (for reviews
see I.e. (49, 58, 91-95)). Much effort has been de-
voted recently to elucidation of the causal chain link-
ing the amyloid precursor protein (a product of chro-
mosome 21) via β/A4 protein to the Alzheimer amy-
loid deposit. Cytoskeleton is involved because neu-
rofibrillary tangles are found as paired helical fila-
ments containing microtubules, neurofilaments, ubi-
quitin and (abnormal) phosphorylated tau-protein
(37, 50). It is not yet known how and why they occur.
This finding is not specific for Alzheimer^ disease and
may be observed in some neurodegenerative disorders.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 8
Kunze and Rüslow: Pathobiochemistry of cytoskelcton 485
Iqbal and coworkers place the abnormalities of the
cytoskeleton at the centre of their hypothesis (93 -
95). They revealed a microtubule assembly defect in
the brain of Alzheimer patients taken immediately
after death. The quantity of tubulin was normal and
isolated tubulin showed the same assembly behaviour
as in controls (94). They concluded that the defective
assembly is due to the abnormal phosphorylation of
tau-protein. Tau protein is reversibly phosphorylated
and regulates the assembly and dissambly of micro-
tubules. It is hypothesized that abnormal phospho-
rylation together with other modifications might sta-
bilize tau-protein so that it becomes a component of
neurofibrillary tangles. Because microtubules are
thought to be required for axoplasmic flow (possibly
as vesicles with dynein and kinesin as motors) any
obstruction of this flow will lead to neurofibrillary
lesions and a disturbed neurotransmission (94—96).
However, in Alzheimer disease the neuronal cytoske-
leton is severely affected. It remains to be established
whether or not the cytoskeleton defect is a primary
factor.
Desmosomes and Skin Defects in Cell-Cell Contact:
Pemphigus Vulgaris and Bullous Pemphigoid
Pemphigus vulgaris and bullous pemphigoid are fatal
skin diseases in which autoantibodies against protein
components of desmosomes or hemidesmosomes
cause loss of cell-cell adhesion, with resultant epider-
mal blisters. Desmosomes are junctions involved in
intercellular adhesion of epithelial cells, whereas hemi-
desmosomes anchor epithelial cells to the basal lam-
ina. Both are characterised at the ultrastructural level
by dense cytoplasmic plaques. They are composed of
a mixture of intracellular attachment proteins called
desmoplakins, and tightly associated with a thick net-
work of keratin filaments (97, 98) which pass along
the surface of the plaque. Transmembrane linker gly-
coproteins called desmogleins bind to the plaques and
interact through their extracellular domains to hold
the adjacent membranes together by a Ca-dependent
mechanism (cadherins). Autoantibodies reactive with
the special desmosomal cadherins, desmoglein I and
desmoplakin I, have been found in pemphigus foli-
aceus (97 — 99) and pemphigus vulgaris (100, 101),
respectively, and obviously play a causal pathogenetic
role. The protein targets of bullous pemphigoid (cell
adhesion to the basement membrane is affected) au-
toantibodies are diverse (102 — 104). Because multiple
antigens are recognized by bullous pemphigoid sera,
care must also be taken in assigning them to a sub-
cellular location. Nevertheless, the action of antibod-
ies against one or more of the desmosomal linker
glycoproteins, leading to disruption of desmosomes
between skin epithelial cells, is the immediate cause
of blistering. The antibodies disrupt desmosomes only
in skin, suggesting that desmosomes in other tissues
may be biochemically different.
Bile Secretion and Intrahepatic Cholestasis
The term cholestasis indicates that defects in secretion
of bile may be due not only to mechanical obstruction
but also to abnormalities in the secretory function of
liver cells (105). All 3 types of cytoskeletal filaments
are involved in the secretion process. Morphological
studies have revealed alterations of canalicular cyto-
plasm, in particular the cytoskeletal elements such as
micro filaments (106). Later pathobiochemical and
pharmacological evidence indicates the involvement
of the cytoskeleton in cholestasis. The search for the
pathogenesis of cholestasis has moved from the bile
duct to the hepatocyte. The cholestasis induced by
cytochalasin B (106) and chronic administration of
phalloidin (107) have gained widespread popularity
as experimental models. Cytochalasin treatment af-
fects actin filaments and leads to a dilatation of can-
aliculi, loss of microvilli and inhibition of tauro-
cholate transport. Phalloidin administration increases
F-actin around the canaliculi and the number of tight
junctions. It disorders the motility of the canaliculi
(107). The familial cholestasis observed in North
American Indian children has been interpreted as a
microfilament dysfunction with a molecular defect in
hepatocyte actin or actin associated proteins (108).
On the other hand, bile acids inhibit the polymerisa-
tion of actin in vitro (109). Thus, the question arises
as to the nature of the primary event: an increased
level of bile acids or defective actin filaments?
Theoretical reasoning also suggests an important role
for actin filaments in bile secretion. Thus, canalicular
contractions have been observed, which may be
caused by pericanalicular actin/myosin filament in-
teractions (55, 107, 110). Furthermore, the cellular
polarization and the positioning and organisation of
the attachment to the neighbouring cell or lumen is
an important factor in hepatocyte function. This is
mainly regulated by the cytoskeleton (55).
An involvement of intermediate filaments in cholesta-
sis is also shown by formation of Mallory bodies. In
contrast to their localisation in alcoholic liver disease,
in cholestasis they are found preferentially in the
periportal area (see 1. c. (54)).
Colchicine, an inhibitor of tubulin polymerization,
decreases bile salt excretion (111). Biliary lipid secre-
tion involves the exocytosis of vesicles consisting
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mainly of phospholipid and cholesterol (112, 113).
Bile acids induce the microtubule-dependent bile and
lipid secretion, whose biochemical mechanism is
poorly understood (113, 114).
Future research will no doubt reveal the nature of the
pathogenetic involvement of the cytoskeleton in such
fatal diseases as primary biliary cirrhosis.
Clinical Chemistry of Cytoskeletal Components
Cytoskeletal proteins have not been found in serum.
Among the cytoskeleton associated proteins only gel-
solin, a G-actin binding protein has been found in
blood. Plasma gelsolin, present at > 200 mg/1, may
have a protective function by promoting the clearance
of actin filaments released during tissue injury. Muscle
may be the predominant secretory source (115). An
increased plasma gelsolin concentration has also been
reported in haemolysis (116). Actin-gelsolin com-
plexes are formed in blood (117). None of these blood
components is diagnostically useful.
Cerebrospinal fluid of patients with neuropathies has
been investigated for the presence of glial fibrillary
acidic protein (118). Although the protein is found in
cases of severe ischemic brain damage, this finding
has no known diagnostic significance (118, 119).
A large number of publications deals with the occur-
rence of antibodies against Cytoskeletal proteins. Au-
toimmune diseases, reactions after organ transplan-
tation, and connective tissue diseases have been stud-
ied extensively. Specific relationships and diagnosti-
cally useful data have, however, not been reported.
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